Geron Forecasts RYTELO Revenue Near High End of Guidance as Community Use Grows
Geron Corporation (NASDAQ:GERN) anticipates that its drug, RYTELO, will generate revenue near the high end of its $230 million to $240 million guidance for 2026. This forecast is supported by three consecutive quarters of growth and a 24% increase in first-half revenue, alongside reduced operating expenses. The company has expanded use into community treatment settings where approximately 80% of lower-risk myelodysplastic syndromes (MDS) patients are treated. Geron's CEO emphasized the shift toward second-line therapy for MDS and earlier treatment lines, supported by updated NCCN guidelines. Additionally, Geron is evaluating partnership or commercial strategies in Europe while maintaining financial flexibility with over $320 million in cash reserves. The company plans to provide an update on its European strategy before year-end. The stock has seen significant movement following recent FDA developments and positive revenue trends.
Topics: MDS treatment expansion operating expenses revenue guidance RYTELO growth